305 related articles for article (PubMed ID: 18322186)
21. Uncoupling of induced protein processing from maturation in dendritic cells exposed to a highly antigenic preparation from a helminth parasite.
Marshall FA; Pearce EJ
J Immunol; 2008 Dec; 181(11):7562-70. PubMed ID: 19017945
[TBL] [Abstract][Full Text] [Related]
22. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
23. Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cells.
Lau AW; Biester S; Cornall RJ; Forrester JV
J Immunol; 2008 Mar; 180(6):3889-99. PubMed ID: 18322197
[TBL] [Abstract][Full Text] [Related]
24. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response.
Cannons JL; Choi Y; Watts TH
J Immunol; 2000 Dec; 165(11):6193-204. PubMed ID: 11086053
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
[TBL] [Abstract][Full Text] [Related]
26. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
Zhu M; Ding X; Zhao R; Liu X; Shen H; Cai C; Ferrari M; Wang HY; Wang RF
J Control Release; 2018 Feb; 272():72-82. PubMed ID: 29325699
[TBL] [Abstract][Full Text] [Related]
27. TLR ligands of ryegrass pollen microbial contaminants enhance Th1 and Th2 responses and decrease induction of Foxp3(hi) regulatory T cells.
Mittag D; Varese N; Scholzen A; Mansell A; Barker G; Rice G; Rolland JM; O'Hehir RE
Eur J Immunol; 2013 Mar; 43(3):723-33. PubMed ID: 23238878
[TBL] [Abstract][Full Text] [Related]
28. Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy.
Ohkusu-Tsukada K; Toda M; Udono H; Kawakami Y; Takahashi K
Eur J Immunol; 2010 Apr; 40(4):1011-21. PubMed ID: 20127675
[TBL] [Abstract][Full Text] [Related]
29. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism.
Harlin H; Podack E; Boothby M; Alegre ML
J Immunol; 2002 Sep; 169(5):2451-9. PubMed ID: 12193714
[TBL] [Abstract][Full Text] [Related]
30. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
31. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.
Agrawal S; Agrawal A; Doughty B; Gerwitz A; Blenis J; Van Dyke T; Pulendran B
J Immunol; 2003 Nov; 171(10):4984-9. PubMed ID: 14607893
[TBL] [Abstract][Full Text] [Related]
32. The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells.
Olivier A; Sainz-Perez A; Dong H; Sparwasser T; Majlessi L; Leclerc C
Eur J Immunol; 2011 Aug; 41(8):2303-13. PubMed ID: 21538349
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
34. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
35. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
[TBL] [Abstract][Full Text] [Related]
36. Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.
Matsushita N; Komine H; Grolleau-Julius A; Pilon-Thomas S; Mulé JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):875-84. PubMed ID: 20054688
[TBL] [Abstract][Full Text] [Related]
37. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
[TBL] [Abstract][Full Text] [Related]
38. IFN-γ stimulates CpG-induced IL-10 production in B cells via p38 and JNK signalling pathways.
Imbrechts M; De Samblancx K; Fierens K; Brisse E; Vandenhaute J; Mitera T; Libert C; Smets I; Goris A; Wouters C; Matthys P
Eur J Immunol; 2018 Sep; 48(9):1506-1521. PubMed ID: 30004580
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.
Jung ID; Shin SJ; Lee MG; Kang TH; Han HD; Lee SJ; Kim WS; Kim HM; Park WS; Kim HW; Yun CH; Lee EK; Wu TC; Park YM
J Immunol; 2014 Aug; 193(3):1233-45. PubMed ID: 24990079
[TBL] [Abstract][Full Text] [Related]
40. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
